Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial (Q46875972)
Jump to navigation
Jump to search
scientific article published on 16 May 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial |
scientific article published on 16 May 2013 |
Statements
1 reference
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial (English)
1 reference
1 reference
1 reference
1 reference
Dino Amadori
1 reference
Massimo Aglietta
1 reference
Barbara Alessi
1 reference
Lorenzo Gianni
1 reference
Gabriella Farina
1 reference
Fernando Gaion
1 reference
Francesco Bertoldo
1 reference
Roberta Rondena
1 reference
Paola Bogani
1 reference
16 May 2013
1 reference
14
1 reference
7
1 reference
663-670
1 reference